Imugene : Presentation by Leslie Chong at 9th Annual Biotech Showcase, San Francisco 9 Jan 17

ASX:IMU

B Cell Based Antibodies for Immuno-Oncology

Leslie Chong

Chief Executive Officer 09-January-2017

1

Notice: Forward Looking Statements

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Imugene Limited's control. Important factors that could cause actual results to differ materially from any assumptions or expectations expressed or implied in this brochure include known and unknown risks. As actual results may differ materially to any assumptions made in this brochure, you are urged to view any forward looking statements contained in this brochure with caution. This presentation should not be relied on as a recommendation or forecast by Imugene Limited, and should not be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

What Does Imugene Do?

We are developing cancer

immunotherapy drugs based on antibodies

IMU's Value Proposition

• Promising science with impeccable provenance in the hottest area of cancer today - immuno oncology

• Broad Pipeline: HER-Vaxx & Mimotopes

• Breast Cancer clinical trial complete & on the cusp of recruitment on our second Phase 1b/2 clinical trial in gastric cancer

• Tight share register with leading Fund Manager,

  Platinum Asset Management

• Frequent, rich, quality news flow ahead

• Axel Hoos Sr. VP of immuno - oncology at GSK, plus team with successful track record in drug development

• Low market cap - undervalued against ASX peers